Tagged with Pricing

pharma With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical and life sciences industry to meet all of their regulatory needs. Kees Baggerman, CEO and founder, highlights the new Gateway…

Pharma The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws. He also discusses the issues of maintaining the sustainability of the French healthcare budget and the importance of increasing European…

pharma Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed by the increasingly high cost of innovative drugs on the healthcare budget. Prof. Smits highlights the benefits that could be…

pharma As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception of the industry. In light of the upcoming Dutch Presidency of the European Union, the Netherlands intends to lead the…

Pharma The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all patients who are in need of them. The Sovaldi case has focused public attention on the pricing of drugs in…

pharma IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his perspective about the Dutch healthcare and life sciences market, the challenges it poses and what companies can expect for the…

Pharma The country manager for BMS South Africa talks about the company’s first to market strategy, and how BMS has shifted the treatment paradigm for oncology in South Africa. Through our platform, we introduce the leaders of the pharma industry, and their partners to our 95,000 readers around the world. With that in mind, would…

Turkey BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical pricing through alternative reimbursement models, and BMS’ role in helping to shape health policy around oncology given their revolutionary immuno-oncology…

Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…

Novartis Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived in Turkey five months ago after working in China for two and a half years. Many executives in Turkey have…

Janssen John O’Hara is the general manager and vice president of Janssen’s facilities in Puerto Rico as well as the head of the Janssen campus. He discusses the affiliate’s rapid growth curve in the last three years through its dedication towards people, processes and community. What are the origins of Janssen’s…

Pharmacy José Pérez de Gracia, president of Farmacias Plaza, discusses the environment between multinational chains and local pharmacies as well as his own plan for extended growth throughout Puerto Rico in the future. A couple of multinational pharmacy chains could be said to control a large monopoly of the market share…